Novel therapeutics for pancreatic adenocarcinoma Journal Article
| Authors: | Lowery, M. A.; O'Reilly, E. M. |
| Article Title: | Novel therapeutics for pancreatic adenocarcinoma |
| Abstract: | The last decade has seen significant developments in the use of combination systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC), with median survival approaching 1 year for select patients treated with FOLFIRINOX in the metastatic setting. However, it is sobering that these developments have been achieved with the use of traditional cytotoxics rather than from successes in the more modern fields of molecularly targeted therapies or immunotherapy. This article highlights several promising therapeutic approaches to PDAC currently under clinical evaluation, including immune therapies, molecularly targeted therapies, strategies for stromal depletion, and targeted therapy for genetically selected patients. © 2015 Elsevier Inc. |
| Keywords: | signal transduction; unclassified drug; overall survival; fatigue; review; cisplatin; cytotoxic agent; fluorouracil; placebo; advanced cancer; drug efficacy; drug safety; nonhuman; capecitabine; gemcitabine; paclitaxel; pancreas cancer; outcome assessment; ipilimumab; unindexed drug; cancer immunotherapy; low drug dose; melanoma; blood toxicity; small interfering rna; rna interference; cyclophosphamide; brca2 protein; cancer therapy; cancer resistance; irinotecan; survival time; immunotherapy; cancer vaccine; folinic acid; cancer stem cell; pancreas adenocarcinoma; tumor immunity; effector cell; hydroxychloroquine; pancreatic adenocarcinoma; kras; autophagy; granulocyte macrophage colony stimulating factor vaccine; oxaliplatin; brca; plerixafor; drug protein binding; tumor microenvironment; randomized controlled trial (topic); novel therapeutics; molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); cell manipulation; veliparib; vismodegib; 8 [4 (1 aminocyclobutyl)phenyl] 9 phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) one; ruxolitinib; human; priority journal; evofosfamide; algenpantucel l; stromal targeting; crs 207 vaccine; irinotecan sucrosofate; necuparanib; recombinant hyaluronidase; tarextumab; t cell manipulation |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 29 |
| Issue: | 4 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-08-01 |
| Start Page: | 777 |
| End Page: | 787 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2015.04.006 |
| PROVIDER: | scopus |
| PUBMED: | 26226910 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work